Phibro Animal Health (PAHC) Cash & Equivalents (2013 - 2026)

Phibro Animal Health's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $54.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 8.99% year-over-year to $54.9 million in Q1 2026; TTM through Mar 2026 was $54.9 million, a 8.99% decrease from a year earlier, with the FY2025 full-year figure at $68.0 million, down 3.65% from the prior year.
• Cash & Equivalents slipped to $54.9 million in Q1 2026 per PAHC's latest filing, from $55.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $76.3 million in Q3 2022 and bottomed at $33.0 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $60.4 million (2025), against an average of $58.6 million.
• Across the five-year window, Cash & Equivalents plunged 51.81% in 2023 and jumped 103.44% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $68.4 million in 2022, then plunged by 51.81% to $33.0 million in 2023, then soared by 103.44% to $67.1 million in 2024, then decreased by 17.28% to $55.5 million in 2025, then retreated by 1.0% to $54.9 million in 2026.
• Per Business Quant, the three latest PAHC Cash & Equivalents figures stand at $54.9 million (Q1 2026), $55.5 million (Q4 2025), and $72.8 million (Q3 2025).